Quipt: Cash-generative core and positive EBITDA, but revenue slips and DOJ probe looms

Snapshot - Quipt Home Medical Corp. (NASDAQ: QIPT)

What's happening inside the company
* Quipt is seeing modest revenue pressure while generating strong operating cash flow. Management is cutting costs, issuing equity incentives and continuing M&A (closed Mediserve on July 1, 2025 for ≈ $2.6M).
* The business remains highly leveraged to reimbursement shifts and billing disruptions: Medicare rate changes (end of Medicare 75/25) and the Change Healthcare cybersecurity incident reduced revenue and collections over the past year.
* Company cooperating with a Department of Justice CID regarding potential claims submissions for CPAP equipment - SEC has completed its inquiry and did not recommend enforcement, but DOJ investigation remains open and creates uncertainty.

Key income-statement positives
* Adjusted EBITDA remains positive: $13,683K (Q) and $41,022K (9M), signalling underlying cash-generative operations after non-cash and one-time adjustments.
* Operating cash flow improved: Net cash provided by operating activities $27,914K (9M 2025) vs $25,404K (9M 2024).
* Gross margin trend improved slightly: Cost of inventory sold down to 25.5% of revenue (Q3 2025) from 27.5% a year earlier; nine-month cost-of-sales 27.0% vs 27.8%-vendor cost reductions helped.
* Interest expense (net) decreased: $1,494K (Q3 2025) vs $1,602K (Q3 2024); nine months $4,642K vs $4,857K - benefit from interest-rate swaps and lower equipment loan balances.
* One-time gain on disposals increased (Q3 gain $872K) - proceeds from returned recalled ventilators improved reported operating income.

Key income-statement negatives
* Revenue declined: $58,289K (Q3 ended June 30, 2025) vs $60,759K (Q3 2024), a −4.1% decline; nine months $177,046K vs $184,583K (−4.1%).
* Net loss widened materially: Net loss $ (3,025)K (Q3 2025) vs $ (1,596)K prior-year quarter; nine months net loss $ (7,151)K vs $ (3,823)K - diluted by higher non-cash stock compensation and other charges.
* Stock-based compensation spiked: $2,120K (Q3 2025) vs $483K (Q3 2024) - March 2025 grants (options + RSUs) are a material non-cash charge and will add ~ $4,490K of unrecognized comp over ~0.6 years.
* Professional fees and legal/DOJ-related costs rose (CID, loss of foreign private issuer status, proxy/activist matters) - operating expense pressure despite payroll reductions.
* Revenue headwinds tied to external factors estimated to have reduced revenue ~$3.0M (Q) and ~$7.0M (9M) year-over-year.

Balance-sheet & liquidity snapshot (as reported June 30, 2025)
* Cash: $11,250K (down from $16,174K at 9/30/24).
* Accounts receivable, net: $27,009K; Inventory: $23,996K; Prepaids/other current: $6,431K → Total current assets $68,686K.
* Total assets: $236,092K; Goodwill $50,733K; Intangible assets, net $63,405K (amortization continuing).
* Total liabilities: $133,556K; Senior credit facility principal outstanding $66,012K (net carrying $64,954K).
* Equipment loans ending balance: $10,538K (current portion $10,525K).
* Lease liabilities - current $5,702K; long-term $11,159K (total $16,861K).
* Shareholders' equity: $102,536K; shares outstanding ~43,444K (as of Aug 8, 2025).

Liquidity & covenant view
* Revolver availability reported ≈ $14,300K; management believes liquidity is sufficient for the next 12 months but cash balance has declined and the company remains levered.
* Senior facility interest: term loans weighted average 7.0% (reprice within 3 months), revolver ~7.6%; interest-rate swaps fixed ~$59M at 3.4-4.4% (weighted combined ~6.8%).

Operational metrics worth watching
* Patients serviced: 151,000 (Q3 2025) vs 153,000 prior-year quarter.
* Equipment set-ups/deliveries: 210,000 (Q3 2025).
* Adjusted EBITDA / cash from operations are the best near-term indicators of solvency versus GAAP net loss.

Catalysts & risks
* Catalysts: restoration of favorable Medicare reimbursement (if Medicare 75/25 returns), further cost reductions, successful small acquisitions (like Mediserve) integrating accretive revenue, and normalization of billing/collections post-Change Healthcare impacts.
* Risks: unresolved DOJ CID, activist/board disputes (proxy activity and related professional fees), continued reimbursement pressure, leverage and upcoming interest-rate repricing, and higher equity dilution via RSU/option settlements.

Bottom line - plain language
Quipt operates a cash-generative core (positive Adjusted EBITDA and stronger operating cash flow), but top-line weakness from reimbursement and billing disruptions pushed GAAP losses wider. Balance sheet shows significant debt (senior facility + equipment loans) and declining cash. The company is buying small targets and spending on equity incentives and legal/professional defenses - sensible for growth and retention, but these choices keep near-term earnings under pressure. The DOJ CID and reimbursement environment are the main macro risks that can swing results materially; watch cash flow, covenant compliance, and any DOJ developments closely.

Sources: Quipt Home Medical Corp. Form 10‑Q for the quarter ended June 30, 2025 (financial statements and MD&A).